Boston, Dec. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Global Viral Vector Manufacturing Markets and Technologies Through 2030” is projected to grow from $6.3 ...
MALVERN, Pa.--(BUSINESS WIRE)--Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback